Literature DB >> 28447153

[Neurodermatitis : Atopy of the skin].

R Fölster-Holst1.   

Abstract

Atopic dermatitis is one of the most common skin diseases and is associated with an impaired quality of life due to tormenting itching and stigmatization. The disease almost always manifests in early childhood and exhibits specific features in this phase, with involvement of the extensor sides of the extremities. During the further course of disease, the typical flexor involvement becomes quite clear and a considerable proportion of patients develop the associated atopic respiratory diseases. Therapeutic and prophylactic measures focus on the prevention of trigger factors, basic skin care, and application of lipid-replenishing creams, as well as patient and parent education. In the case of exacerbation, anti-inflammatory drugs are treatment of choice.

Entities:  

Keywords:  Immune system; Patient education; Pruritus; Quality of life; Stigmatization

Mesh:

Substances:

Year:  2017        PMID: 28447153     DOI: 10.1007/s00347-017-0495-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  33 in total

1.  T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells.

Authors:  Mübeccel Akdis; Axel Trautmann; Sven Klunker; Isabelle Daigle; Umut C Kucuksezer; Wolfgang Deglmann; Rainer Disch; Kurt Blaser; Cezmi A Akdis
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

2.  Noninvasive stratum corneum sampling and electron microscopical examination of skin barrier integrity: pilot study with a topical glycerin formulation for atopic dermatitis.

Authors:  S Daehnhardt-Pfeiffer; C Surber; K-P Wilhelm; D Daehnhardt; G Springmann; M Boettcher; R Foelster-Holst
Journal:  Skin Pharmacol Physiol       Date:  2012-03-06       Impact factor: 3.479

3.  Stress and the skin.

Authors:  A Reich; A Wójcik-Maciejewicz; A T Slominski
Journal:  G Ital Dermatol Venereol       Date:  2010-04       Impact factor: 2.011

4.  Systemic therapies for severe atopic dermatitis in children and adults.

Authors:  Carsten Flohr; Alan D Irvine
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

5.  Point prevalence and risk factors for food allergy in a cohort of 386 children with atopic dermatitis attending a multidisciplinary dermatology/paediatric allergy clinic.

Authors:  Claire Mailhol; Françoise Giordano-Labadie; Valérie Lauwers-Cances; Alfred Ammoury; Carle Paul; Fabienne Rance
Journal:  Eur J Dermatol       Date:  2014 Jan-Feb       Impact factor: 3.328

6.  [Associated diseases and differential diagnostic considerations in childhood atopic eczema].

Authors:  C Jenneck; R Foelster-Holst; T Hagemann; N Novak
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

7.  Characteristics of peripheral blood CD4+CD25+ regulatory T cells and related cytokines in severe atopic dermatitis.

Authors:  Yun-Ying Zhang; Ao-Xue Wang; Lu Xu; Nan Shen; Jie Zhu; Cai-Xia Tu
Journal:  Eur J Dermatol       Date:  2016-06-01       Impact factor: 3.328

Review 8.  Mechanisms and treatment of allergic disease in the big picture of regulatory T cells.

Authors:  Cezmi A Akdis; Mübeccel Akdis
Journal:  J Allergy Clin Immunol       Date:  2009-04       Impact factor: 10.793

9.  Birch pollen influence the severity of atopic eczema - prospective clinical cohort pilot study and ex vivo penetration study.

Authors:  Regina Fölster-Holst; Jagoda Galecka; Sigo Weißmantel; Ute Dickschat; Frank Rippke; Kerstin Bohnsack; Thomas Werfel; Katja Wichmann; Matthias Buchner; Thomas Schwarz; Annika Vogt; Jürgen Lademann; Martina C Meinke
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-10-29

10.  Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.

Authors:  Eric L Simpson; Joanne R Chalmers; Jon M Hanifin; Kim S Thomas; Michael J Cork; W H Irwin McLean; Sara J Brown; Zunqiu Chen; Yiyi Chen; Hywel C Williams
Journal:  J Allergy Clin Immunol       Date:  2014-10       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.